Key clinical point: Compared to 3-dimensional conformal radiotherapy, intensity modulated radiation therapy was associated with improved target coverage and reduced volume of skin and nearby joint treated to higher doses, warranting further investigation to understand if preoperative radiotherapy technique leads to reduced risks of long-term functional complications such as wounds and musculoskeletal injury in children with high-grade extremity nonrhabdomyosarcoma soft-tissue sarcomas.
Main finding: The 18 patients who received intensity modulated radiotherapy had better clinical target volume coverage to 100% of the prescription dose compared with the 38 patients who received 3-dimensional conformal radiotherapy plans (median clinical target volume coverage, 92.7% vs 98.6%; P = .011). Intensity modulated radiotherapy was also associated with reduced volume of skin receiving 45 Gy or more to the adjacent joint compared with 3-dimensional conformal radiotherapy (median, 1.1% vs 13.2%; P = .018).
Study details: The study evaluated patients who large, high-grade, extremity nonrhabdomyosarcoma soft-tissue sarcomas and were enrolled in the Children's Oncology Group ARST0332 trial where they received neoadjuvant ifosfamide/doxorubicin, then chemoradiotherapy (45 Gy and ifosfamide) and surgery followed by postoperative radiotherapy in the event of positive surgical margins. Of the 113 patients, 56 patients had preoperative radiotherapy plans that were analyzed with respect to radiotherapy technique.
Disclosures: The authors declared having no relevant disclosures.
Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
Thirty-eight patients (65%) received 3-dimensional conformal RT (3D-CRT) and In patients without target overlap with the skin, IMRT use was associated with reduced percent volume of skin receiving 45 Gy or more (V45Gy) compared with 3D-CRT (median, 1.6% vs 6.3%, respectively; P = .005).
Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
This Week's Must Reads
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
QC measures improve with CMS Oncology Care Model, Rocque G et al. J Oncol Pract. 2019. doi: 10. 1200/JOP.18.00390.
Women less likely to receive industry funds, Weng JK et al. JAMA Netw Open. 2019 Jan. 25. doi: 10.1001/jamanetworkopen.2018.7377.
A shift in Medicare drug coverage may boost costs for patients, Hwang TJ et al. JAMA Int Med. 2019. doi: 10.1001/jamainternmed.2018.6417.
Must Reads in Sarcoma & GIST
Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
Expanded genetic analyses of myxofibrosarcomas may guide precision therapies, Ogura K et al. Nature Communications; 17 July 2018. https://doi.org/10.1038/s41467-018-03891-9
Malignant tenosynovial giant cell tumors appear to originate from synoviocytes, Al-Ibraheemi A et al. Modern Pathology; 11 Sept. 2018. https://doi.org/10.1038/s41379-018-0129-0
Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups, Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0
Increasing pannexin 1 levels might be a novel treatment for rhabdomyosarcoma , Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4